Materials • Major Chemicals
$60.55 ▼ -2.01
(-3.21%)
MKT CAP: $9.94B • VOL: 1.53M
52W L $40 52W H $91
SOLS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.89B | $3.77B | $3.65B |
| YoY Revenue Growth % | +3.1% | +3.3% | — |
| Gross Profit | $1.25B | $1.31B | — |
| Gross Margin % | 32.2% | 34.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $279.7M | $700.9M | $732.8M |
| Operating Margin % | 7.2% | 18.6% | 20.1% |
| Net Income (GAAP) | $237.0M | $594.0M | $621.0M |
| EBITDA (Normalized) | $548.5M | $937.7M | $864.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $455.0M | $842.0M | $760.0M |
| Capital Expenditures (CapEx) | $336.0M | $296.0M | $164.2M |
| Free Cash Flow (FCF) | $119.0M | $546.0M | $595.8M |
| FCF Margin % | 3.1% | 14.5% | 16.3% |
| Return on Invested Capital (ROIC %) | 7.8% | 21.3% | 17.5% |
| Cash & Short-Term Equivalents | $534.0M | $661.0M | — |
| Total Debt (Short + Long Term) | $1.97B | $0 | $1.28B |
| Total Stockholders' Equity | $1.41B | $3.26B | $2.62B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SOLS.